New treatment shows vision benefit in Age Related Macular Degeneration

COCONUT CREEK, Fla. - April 16, 2020 - PRLog -- Age Related Macular Degeneration- specifically dry AMD-  will affect almost 200 million people world-wide in 2020.   An approach, pioneered by MD Stem Cells, using bone marrow stem cells from the actual patient has now shown visual improvement for 63% of dry AMD eyes and stability in another 34%, demonstrating statistical significance in helping patients with this blinding disease.  Results were recently published in the Medicines Journal- a highly regarded international medical journal.

The Stem Cell Treatment Ophthalmology Study has been treating many different eye diseases since 2013 using the patient's own bone marrow stem cells (BMSC). Different optic nerve diseases, NAION, LHON, DOA, optic atrophy; as well as several retinal diseases including Retinitis Pigmentosa, Ushers and now AMD have all shown benefit.  MD Stem Cells now has 14 world class medical and scientific publications primarily reporting their clinical results in ophthalmology. This is vastly more than any other stem cell research group in this field- which should be important to patients seeking experienced providers.  Different optic nerve diseases, NAION, LHON, DOA, optic atrophy; as well as several retinal diseases including Retinitis Pigmentosa, Ushers and now AMD have all shown benefit. The study is Institutional Board Approved and National Institutes of Health registered on www.clinicaltrials.gov  NCT 03011541.

The highlight of the report was that 63% of dry AMD eyes treated and followed had vision improvement.  This ranged from 2.5% to 44.6% with an average of 27.6% on a scientific vision scale called LogMAR.  An additional 34% of eyes remained stable for the follow up period- important because many of the eyes had previously been losing vision. The findings were highly statistically significant with p <  0.001 meaning that the results overwhelmingly met that medical standard and confirming that the BMSC treatment was responsible for the improvements seen.

"Following multiple patient treatments and over a dozen peer-reviewed papers, our studies have shown that a patient's own bone marrow stem cells (BMSC) can have positive effects on different retinal and optic nerve diseases" explains Dr. Levy, CEO and Chief Science Officer for MD Stem Cells.

Dr. Levy concludes: "as we continue SCOTS 2, we can conclude that patients with dry AMD choosing to participate in the study have a strong likelihood of either improving or stabilizing their vision. "

Patients may receive information about SCOTS 2 by emailing stevenlevy@mdstemcells.com  ,using the contact us page on www.mdstemcells.com calling 203-423-9494.  The Stem Cell Ophthalmology Study 2 is enrolling patients with different retina  and optic nerve diseases. MD Stem Cells has no grant support and is not a pharmaceutical company; these are patient sponsored studies and the patients pay for both treatment and travel.